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Objective: The purpose of this study is to evaluate the clinical characteristics, pathology, treatment
outcomes, and survival of primary testicular lymphoma (PTL) patients treated at our hospital after 1990.
Related literature was reviewed.
Materials and methods: We retrospectively enrolled patients diagnosed with PTL between January 1990
and September 2013 in our institute. Clinical features, pathology, and overall survival were analyzed.
Results: 24 patients were enrolled. They had a mean age at diagnosis of 65.0 years (range 10e84 y),
mean follow-up duration 57.0 months (range 3e182 mo), and median overall survival of 38 months
(range 4.0e184.7 mo). The most common pathology subtype was diffuse large B-cell lymphoma (n ¼ 21,
87.5%). Fourteen patients (58.3%) achieved complete remission of disease and ﬁve patients (20.8%)
achieved partial remission after treatment. Three patients had a relapse of disease after complete
remission: one in the brain parenchyma, one in the pelvis soft tissue and omentum, and one in the left
pyriform muscle. Three patients had metastasis after partial remission of disease: two in the brain
parenchyma and one in the cauda equina. By univariate analysis, the factors signiﬁcantly associated
with superior overall survival were primary tumor diameter < 7.5 cm, serum lactate dehydrogenase 
250 U/L, Ann-Arbor Stage IE/II, and International Prognostic Index (IPI)  1 (p < 0.05). Rituximab-
containing treatment did not show overall survival beneﬁts in our series. By multivariate analysis,
IPI  1 showed statistical signiﬁcance (p ¼ 0.019), suggesting a potential prognostic value of IPI in
evaluating PTL patients.
Conclusions: The overall survival of PTL patients is poor, especially those with extensive disease (Stage III/
IV). The IPI have a prognostic role in PTL. The use of rituximab in the treatment regimen of PTL does not
seem to improve survival in our series.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Primary testicular lymphoma (PTL) is a rare but aggressive
malignant tumor. It constitutes only 1e2% of non-Hodgkin lym-
phoma, and population-based studies have estimated the incidence
at 0.09e0.26/100,000 per year.1 However, lymphoma remains they, Taipei Veterans General
City 11217, Taiwan.
ociation. Published by Elsevier Tamost common testicular neoplasm in men > 60 years of age. The
usual presentation is a painless testis mass which grows slowly
over weeks or months, with either unilateral or bilateral involve-
ment. Typically, PTL is diagnosed after radical orchiectomy, and the
most frequent histological subtype is diffuse large B-cell lymphoma
(DLBCL), although other histological subtypes have been
described.2
Currently, there are no gold standard treatment guidelines for
PTL. The available data to date are from nonrandomized studies or
retrospective series. Generally, the common treatment strategies
include radical orchiectomy, followed by chemotherapy and/or
radiotherapy. Rituximab, a chimeric monoclonal antibody againstiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Patient characteristics.
Characteristics Patient number (%)
Age (y)
> 60 16 (66.7)







T-cell lymphoma 1 (4.2)







Low (0e1) 10 (41.7)
Loweintermediate (2) 5 (8.3)
Higheintermediate (3) 6 (25.0)
High (4e5) 3 (12.5)
DLBCL ¼ diffuse large B-cell lymphoma; IPI ¼ International Prognostic Index.
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However, its impact on outcomes in PTL remains unclear, and may
be less deﬁnitive than in nodal DLBCL.1
In this retrospective study, we evaluated the clinical character-
istics, pathology, and treatment outcomes of 24 PTL patients
treated at our hospital after 1990. Related literature was also
reviewed for a better understanding of this rare malignancy.
2. Materials and methods
We retrospectively enrolled patients diagnosed with PTL be-
tween January 1990 and September 2013 in our institute (Taipei
Veterans General Hospital, Taiwan). The diagnosis of PTL wasmade
if the testes were the primary site of the disease or at least the
main site of involvement, without or with only minor nodal
involvement.3 Patients with a lymphoma history and those lost to
follow-up were excluded. All patients underwent computed to-
mography (CT) scan from the neck to pelvis, whole-body bone
scan, and bone marrow biopsy for staging. Potential prognostic
factors, including age, primary tumor diameter, serum lactate de-
hydrogenase (LDH), Ann-Arbor stage, International Prognostic
Index (IPI) score, and the use of rituximab-containing regimen,
were evaluated. IPI is a clinical tool developed by oncologists to aid
in predicting the prognosis of patients with aggressive non-
Hodgkin lymphoma. One point is assigned for each of the
following risk factors: age > 60 years, Stage III/IV disease, elevated
serum LDH, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status > 1, and more than one extranodal site. Based on IPI
scores, patients could be classiﬁed into low-risk group (IPI  1) or
intermediateehigh-risk group (IPI  2). The Ann-Arbor staging is
the staging system for lymphomas. Stage I indicated lymphoma
involving only a single lymph node (Stage I) or a single extra-
lymphatic organ (Stage IE); Stage II indicated lymphoma involving
two separate regions, with both the affected areas being conﬁned
to one side of the diaphragm; Stage III indicated that lymphoma
has spread to both sides of the diaphragm; and Stage IV indicated
diffuse or disseminated involvement of one or more extra-
lymphatic organs, including any involvement of the liver, bone
marrow, or lung. Patients received further treatment including
chemotherapy with or without rituximab, intrathecal chemo-
therapy, and radiotherapy to the contralateral testis. The standard
chemotherapy regimen is CHOP before the rituximab era and R-
CHOP after the rituximab era. The standard R-CHOP regimen is as
follows: rituximab 700 mg, cyclophosphamide 750 mg/m2, doxo-
rubicin 50 mg/m2, oncovin 1.4 mg/m2, and prednisolone 40mg by
mouth twice daily from Days 2 to 5; the regimen was given every
3 weeks. Doxorubicin may be replaced by etoposide 50 mg/m2 if
the patient's cardiac function is poor. The standard intrathecal
chemotherapy includes methotrexate 15 mg, cytarabine 50 mg,
and dexamethasone 5 mg. The standard dosage of contralateral
testis radiotherapy is 30 Gy. The overall survival (OS) was calcu-
lated from the date of diagnosis to the time of mortality, or the
time of last follow-up for survivors. The KaplaneMeier survival
curve was plotted for patients of each group, and the differences
between the curves were examined using the log-rank test. Sta-
tistical analyses were performed using SPSS version 19.0 (SPSS,
Chicago, IL, USA).
3. Results
From January 1990 to September 2013, 24 patients with PTL
were diagnosed and treated in our institute. Their mean age at
diagnosis was 65.0 years (range 10e84 y), mean follow-up dura-
tion was 57.0 months (range 3e182 mo), and median OS was
38 months (range 4.0e184.7 mo). Radical orchiectomy wasperformed in 23 patients, and only one patient received open testis
biopsy for diagnosis. The most common pathology subtype is
DLBCL (n ¼ 21, 87.5%). Patient's clinical characteristics are sum-
marized in Table 1.3.1. Treatment response
The treatment modalities and outcomes are summarized in
Table 2. Of the 24 patients, two (Cases 13 and 22) did not receive
further treatment due to poor performance status and rapid disease
progression resulting in mortality. The remaining 22 patients
received further systemic chemotherapy, with or without intra-
thecal central nervous system (CNS) prophylaxis or contralateral
testis prophylactic irradiation. Fourteen patients (58.3%) had com-
plete remission of disease, but three patients had disease relapse,
including one with brain metastasis after 7 years, one with left
pyriform muscle metastasis at 11 months, and one with metastasis
to the pelvis soft tissue and omentum at 16 months. Five patients
(20.8%) had partial remission of disease, with three patients had
disease progression, including two with brain metastasis at
9 months and 13 months, respectively, and one with cauda equina
metastasis at 6 months.3.2. Prognostic factors
Patients were grouped according to age, primary tumor diam-
eter, serum LDH level, Ann-Arbor stage, IPI scores, and rituximab-
containing regimen. Based on the Ann-Arbor staging system, pa-
tients were separated into thosewith limited disease (Stage IE/II) or
extensive disease (Stage III/IV). According to IPI scores, patients
could be classiﬁed into low-risk group (IPI  1) or inter-
mediateehigh-risk group (IPI  2). The statistical results are sum-
marized in Table 3 and Figure 1. By univariate analysis, the factors
signiﬁcantly associated with a superior OS were primary tumor
diameter < 7.5 cm, serum LDH  250 U/L, and limited and low-risk
disease (p < 0.05). Treatment with rituximab-containing regimen
did not show OS beneﬁt in our series. By multivariate analysis, only
those with low-risk disease (IPI  1) showed signiﬁcance
(p ¼ 0.019), suggesting that IPI score had prognostic value in
evaluating patients with PTL.
Table 2
Clinical characteristics, treatment methods, and outcome of 24 patients with primary testicular lymphoma.
Case Age (y) Site Pathology Ann-Arbor stage IPI score Initial management Subsequent treatment Follow-up (mo), status
1 58 Left DLBCL IV 1 Radical orchiectomy C/T 34, expired
2 59 Right T-cell lymphoma III 2 Radical orchiectomy C/T 6, expired
3 80 Left DLBCL IE 2 Radical orchiectomy C/T 93, expired
4 71 Right DLBCL II 2 Radical orchiectomy C/T 89, expired
5 73 Right DLBCL IV 3 Radical orchiectomy C/T 16, expired
6 27 Bilateral DLBCL IV 3 Biopsy C/T 4, expired
7 67 Left DLBCL IE 1 Radical orchiectomy C/T 65, expired
8 68 Left Burkitt's lymphoma IE 1 Radical orchiectomy C/T 182, alive
9 56 Left DLBCL IE 0 Radical orchiectomy C/T 180, alive
10 70 Right DLBCL IV 4 Radical orchiectomy C/T 9, expired
11 34 Bilateral DLBCL IE 2 Radical orchiectomy C/T 23, expired
12 10 Right DLBCL II 1 Radical orchiectomy C/T þ IT 158, alive
13 79 Right DLBCL IE 1 Radical orchiectomy Nil 42, expired
14 80 Left DLBCL IE 1 Radical orchiectomy C/T 137, alive
15 72 Left DLBCL II 3 Radical orchiectomy C/T with rituximab þ R/T 21, expired
16 84 Left DLBCL IE 1 Radical orchiectomy C/T 120, alive
17 64 Left Burkitt's lymphoma IV 4 Radical orchiectomy C/T þ IT þ R/T 5, expired
18 78 Right DLBCL IV 3 Radical orchiectomy C/T with rituximab þ IT 50, expired
19 57 Right DLBCL IE 0 Radical orchiectomy C/T with rituximab þ IT 70, expired
20 80 Right DLBCL II 4 Radical orchiectomy C/T with rituximab 4, expired
21 79 Right DLBCL II 3 Radical orchiectomy C/T with rituximab 5, expired
22 73 Right DLBCL IE 2 Radical orchiectomy Nil 3, expired
23 58 Left DLBCL IE 1 Radical orchiectomy C/T with rituximab þ IT 44, alive
24 81 Left DLBCL II 3 Radical orchiectomy C/T with rituximab 7, expired
C/T ¼ chemotherapy; DLBCL ¼ diffuse large B-cell lymphoma; IPI ¼ International Prognostic Index; IT ¼ intrathecal chemotherapy; R/T ¼ contralateral testis irradiation.
Table 3
Results of univariate and multivariate analyses of prognostic factors of overall survival.
Variables n Categorization Univariable Multivariable
HR, 95% CI p HR, 95% CI p
Age (y) 8  60 1.413, 0.503e3.972 0.512 d d
16 > 60
Tumor diameter (cm) 17  7.5 3.192, 1.140e8.934 0.027 2.914, 0.944e8.998 0.063
7 > 7.5
LDH (U/L) 14  250 2.678, 1.013e7.078 0.047 2.916, 0.752e11.304 0.1216
10 > 250
Ann-Arbor stage 17 I/II 3.968, 1.347e11.689 0.012 3.000, 0.809e11.125 0.1005
7 III/IV
IPI score 10  1 6.671, 2.129e20.898 0.001 4.559, 1.288e16.14 0.0187
14 2
Rituximab 17 Not contained 1.900, 0.682e5.291 0.220 d d
7 Contained
CI ¼ conﬁdence interval; HR ¼ hazard ratio; IPI ¼ International Prognostic Index; LDH ¼ lactate dehydrogenase.
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In this report, we presented 24 patients with PTL treated in our
hospital after 1990. The mean patient age at diagnosis was
65.0 years, and the most pathological subtype is DLBCL. Typical
presentation is a unilateral or bilateral painless testicular swelling
or mass. The scrotal sonography of testicular lymphoma might
appear as a diffusely hypoechoic but hyperemic testicle or a focal
testicular mass with increased blood ﬂow.4 In our series, radical
orchiectomy was performed for both diagnostic and therapeutic
purposes, and only one patient received open testis biopsy for the
diagnosis of bilateral testicular mass.
Ann-Arbor staging is the staging system for lymphomas, both in
Hodgkin's and non-Hodgkin lymphomas, and is widely used by
oncologists. Ahmad et al5 reported that up to 90% of patients have
Stage I or II disease at diagnosis (60% and 30%, respectively), and
35% had bilateral testicular involvement. In our series, 41.6% of
patients was diagnosed Stage I disease and 29.2% was diagnosed
with Stage II disease. Bilateral testis involvement was only seen in
8.3% of patients. The OS of PTL is poor, especially in those with
extensive disease (Stage III/IV).Like Ann-Arbor stage, IPI was also developed by oncologists to
predict the prognosis of patients with aggressive non-Hodgkin
lymphoma. Jia et al6 reported that, besides IPI, a primary testicular
tumor diameter larger than 7.5 cmwas a poor prognostic factor for
PTL patients. In our series, the OS was different between low-risk
group (IPI  1) and intermediateehigh-risk group (IPI  2) pa-
tients. The OS was also different between patients with a primary
testis tumor diameter of smaller than 7.5 cm and those with tu-
mors larger than 7.5 cm. By multivariate analysis, only those with
IPI  1 had signiﬁcantly better survival (p ¼ 0.019) in our series,
indicating that IPI score still had its predictive value in evaluating
PTL patients.
The optimal management of PTL has not yet been established.
Several studies have demonstrated that orchiectomy alone should
not be considered as the sole treatment in patients with Stage I
disease.7e9 Early studies have reported that if these patients were
treated with surgery alone, most would experience relapse within
2 years, implying that in PTL, widespread microscopic disease is
present at diagnosis.10 Furthermore, relapse in the contralateral
testis occurred in 5e35% of PTL patients.11,12 The International
Extranodal Lymphoma Study Group had conducted a large
Figure 1. Cumulative survival rate between (A) age  60 years and > 60 years, (B) primary tumor diameter  7.5 cm and >7.5 cm, (C) lactate dehydrogenase  250 U/L and > 250 U/
L, (D) Ann-Arbor Stage IE/II and III/IV, (E) IPI  1 and  2, and (F) chemotherapy with and without rituximab. C/T ¼ chemotherapy; IPI ¼ International Prognostic Index;
LDH ¼ lactate dehydrogenase.
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These studies have the best evidence to date. The studies pro-
moted combined treatment for PTL regardless of stages, including
radical orchiectomy, followed by anthracycline-based chemo-
therapy (CHOP) plus rituximab, intrathecal methotrexate CNS
prophylaxis, and contralateral prophylactic testicular irradiation.
Nonetheless, CNS prophylaxis warrants further investigation. The
best strategy to prevent CNS relapse is still debatable, and a new
prospective study by the International Extranodal Lymphoma
Study Group is ongoing.13
In our series, two patients did not receive any further treatment
after radical orchiectomy due to poor performance status and rapid
disease progression resulting in mortality. The other 22 patientsreceived further systemic chemotherapy. Only ﬁve patients
received intrathecal prophylaxis. In our institute, intrathecal
chemotherapy prophylaxis was still not routinely performed as the
ﬁrst-line treatment, since intrathecal chemotherapy has its limi-
tations. First, in PTL patients with CNS relapse, the brain paren-
chyma is the most frequent relapse or metastasis site rather than
themeninges. Hence, prophylactic intrathecal chemotherapymight
not be effective.14 In our series, only one patient suffered from brain
parenchyma relapse after complete remission. Three patients with
partial remission had further CNS metastasis, including two in the
brain parenchyma and one in the cauda equina. The relapse or
metastasis sites were not the meninges. Second, PTL patients are
usually elderly, who may have degenerated spine disease causing
W.-J. Chen et al. / Urological Science 27 (2016) 96e100100difﬁculty in performing lumbar puncture, and theymay not tolerate
aggressive CNS prophylaxis. In addition, lumbar puncture may
cause complications, such as hemorrhage and infection, andmay be
fatal in severe conditions.
Rituximab, a chimeric monoclonal antibody against the pro-
tein CD20, was approved by the United State Food and Drug
Administration in 1997 to treat B-cell non-Hodgkin lymphoma
resistant to chemotherapy regimens. The combination of ritux-
imab and CHOP chemotherapy was later proven to be superior to
CHOP alone as treatment of DLBCL, and is currently used as the
ﬁrst-line treatment of DLBCL. However, although rituximab had
improved the outcome of DLBCL, its impact on the outcome of
PTL remained unclear. Gundrum et al8 conducted a study using
the Surveillance, Epidemiology, and End Results database to
analyze the potential impact of the use of rituximab on PTL
survival. The study concluded that the use of rituximab in clinical
practice did not seem to improve the ﬁrst 5-year outcome. In our
series, seven patients received rituximab-containing chemo-
therapy, but these patients did not show better OS compared
with those receiving traditional anthracycline-based
chemotherapy.
In the current rituximab era, relapse is still the major failure
pattern in patients with PTL. In recent years, some studies using
gene expression assays have been published to investigate any
unique gene expression in primary testicular DLBCL, which may
serve as a potential target for immunotherapy or anti-cancer drug
therapy. The distinctive gene expression proﬁling signature of pri-
mary testicular DLBCL was relevant to upregulation of some on-
cogenes and genes encoding components of B-cell receptor
signaling and proliferation, and downregulation of some anti-
oncogenes.15,16 Results of these protein or gene level analysis sug-
gested that new agents may be promising for primary testicular
DLBCL patients in the future.
This retrospective study has limitations. The study population is
small and the treatment protocols are diverse, making it difﬁcult to
analyze relevant treatment prognostic factors.
In conclusion, the major pathology of PTL is DLBCL, and most
patients are diagnosed in Ann-Arbor Stage IE/II disease. The OS is
poor, especially in those with extensive disease (Stage III/IV). In
addition to radical orchiectomy for local control, systemic chemo-
therapy is still needed. In this study, the CNS relapse site is the brain
parenchyma, so prophylactic intrathecal chemotherapy may not be
beneﬁcial to PTL patients. IPI is prognostic in evaluating PTL pa-
tients and the OS is better in low-risk group patients (IPI  1). The
use of rituximab in the treatment regimen does not seem to
improve the survival in our series.Conﬂicts of interest
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